Novartis, Versant hope to repeat Chinook’s success by arming kidney biotech Borealis with $150M

Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease-focused biotechs that it has partnered with VC firm Versant Ventures to create another company in a similar mold.